PUBLISHER: The Business Research Company | PRODUCT CODE: 2045394
PUBLISHER: The Business Research Company | PRODUCT CODE: 2045394
Human fibroblast growth factor (hFGF) refers to a group of naturally occurring proteins in the human body that play essential roles in cell growth and development. These growth factors function as signaling molecules, binding to specific fibroblast growth factor receptors (FGFRs) on cell surfaces, initiating a series of intracellular signals that regulate cell proliferation, survival, and angiogenesis.
The prominent product types of human fibroblast growth factor include animal derived, natural, and recombinant. Animal-derived variants are extracted from animal tissues and used in research and therapeutic applications for promoting cell growth and regeneration. Available forms include liquid, lyophilized, and powder, distributed through direct sales, distributors, and e-commerce channels. Applications include cell proliferation, diagnostics, drug screening, and tissue engineering, serving biotech companies, hospitals, pharmaceutical companies, and research institutes.
Tariffs have impacted the hFGF market by increasing the cost of imported proteins and reagents, disrupting supply chains for recombinant and natural growth factors. The animal-derived and recombinant hFGF segments, particularly in North America and Europe, are most affected due to dependency on international suppliers. Tariffs have led to higher production costs for biotech companies and research institutes, slowing adoption in some applications. However, tariffs have also encouraged local manufacturing, innovation in cost-effective formulations, and diversification of supply sources, which can strengthen the market's resilience.
The human fibroblast growth factor market research report is one of a series of new reports from The Business Research Company that provides human fibroblast growth factor market statistics, including human fibroblast growth factor industry global market size, regional shares, competitors with a human fibroblast growth factor market share, detailed human fibroblast growth factor market segments, market trends and opportunities, and any further data you may need to thrive in the human fibroblast growth factor industry. This human fibroblast growth factor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human fibroblast growth factor market size has grown rapidly in recent years. It will grow from $1.1 billion in 2025 to $1.22 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growth in regenerative medicine research, increasing demand for human tissue derived proteins, rising investment in biotech R&D, expansion of hospital and research institute networks, adoption of hfgf in diagnostic applications.
The human fibroblast growth factor market size is expected to see rapid growth in the next few years. It will grow to $1.83 billion by 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing adoption of recombinant hfgf products, growth in tissue engineering and cell therapy markets, rising use in high-throughput drug screening, advancements in protein stabilization technologies, expansion of direct sales and e-commerce channels. Major trends in the forecast period include increasing development of recombinant hfgf variants, rising use of hfgf in tissue engineering applications, expansion of high-purity and lyophilized formulations, growing adoption of hfgf in drug screening platforms, integration of hfgf solutions with cell proliferation research.
The rising incidence of chronic diseases is expected to drive the growth of the human fibroblast growth factor market in the coming years. Chronic diseases are long-lasting health conditions, typically persisting for three months or more, often progressing slowly and rarely cured completely, although symptoms can be managed, often requiring ongoing medical attention or long-term medication. The increase in chronic diseases is linked to lifestyle changes and environmental factors associated with modern life, accumulating over time to cause long-term health issues. Human fibroblast growth factor aids in preventing chronic diseases by enabling tissue repair, new blood vessel formation, and reducing chronic inflammation, thereby lowering the risk and progression of long-term health conditions. For instance, in 2025, The Northern Arizona Medical Group, a US-based healthcare provider, projected that nearly three-quarters of the global population will live with at least one chronic illness, with prevalence continuing to rise. In the United States in 2023, approximately 76.4% of adults reported having at least one chronic condition, and 51.4% had two or more. Consequently, the increasing incidence of chronic diseases is driving the growth of the human fibroblast growth factor market.
Leading companies operating in the human fibroblast growth factor market are advancing synthetic growth factor engineering, enabling the creation of peptide or protein mimetics that replicate the biological activity of native FGFs while offering greater stability, reduced degradation, improved receptor specificity, and lower production costs. Synthetic growth factor engineering involves designing artificially created or modified molecules to mimic or enhance natural growth factor activity while improving stability, specificity, and manufacturability. For example, in October 2024, PeptiGrowth Inc, a Japan-based biotechnology company, launched a novel synthetic peptide growth factor that mimics natural growth factor activity while improving stability and efficiency. The peptides provide prolonged activity in cell culture systems, reducing the need for frequent media replacement and ensuring consistent experimental results.
In August 2023, Danaher Corporation, a U.S.-based global science and technology company specializing in life sciences, diagnostics, and biotechnology solutions, acquired Abcam plc for approximately $5.7 billion. Through this acquisition, Danaher gained access to Abcam's extensive portfolio of recombinant proteins, antibodies, and life science research reagents, including human fibroblast growth factors widely used in cell culture, stem cell research, and regenerative medicine applications. Abcam plc is a UK-based biotechnology company specializing in the development and supply of high-quality antibodies, recombinant proteins, and assays for research, diagnostic, and drug discovery applications.
Major companies operating in the human fibroblast growth factor market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Bio-Techne Corporation, STEMCELL Technologies Inc., GenScript Biotech Corporation, Promega Corporation, Sino Biological Inc., Cell Signaling Technology Inc, ACROBiosystems Co. Ltd., RayBiotech Inc., Proteintech Group Inc., PromoCell GmbH, Creative Biolabs Co. Ltd., BPS Bioscience Inc., MedChemExpress LLC, ProSpec-Tany Technogene Ltd., Novoprotein Scientific Inc., Elabscience Biotechnology Inc., Enzo Life Sciences Inc.
North America was the largest region in the human fibroblast growth factor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human fibroblast growth factor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the human fibroblast growth factor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The human fibroblast growth factor (hFGF) market includes of revenues earned by entities by providing services such as wound healing and tissue repair, angiogenesis, cosmetic and dermatology applications, drug development services, metabolic and systemic health support, and laboratory and biotechnology applications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The human fibroblast growth factor (hFGF) market consists of sales of wound healing gels and creams, ophthalmic preparations, bone and cartilage repair products, anti-aging serums and creams, cell culture supplements, and drug screening kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Human Fibroblast Growth Factor Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses human fibroblast growth factor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for human fibroblast growth factor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human fibroblast growth factor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.